Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Prelude Therapeutics Inc (PRLD) stock has plummeted to a 52-week low, trading at just $0.67, marking a significant downturn for the biopharmaceutical company. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 7.04, though it’s currently rated as having WEAK overall financial health. Over the past year, the stock has faced a staggering decline, with the 1-year change data revealing a sharp drop of -83.59%. While four analysts have recently revised their earnings expectations upward, InvestingPro analysis indicates the company is quickly burning through cash, with negative free cash flow of -$107.56 million in the last twelve months. Investors have watched with concern as the company’s shares have steadily decreased in value, reaching this new low point. The substantial decrease over the year reflects investor sentiment and market conditions that have weighed heavily on the company’s market valuation, which now stands at $36.93 million. InvestingPro subscribers can access 12 additional key insights and a comprehensive Pro Research Report for deeper analysis of PRLD’s financial position and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.